Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | MAOA | P21397 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | CCNT1 | O60563 | 4/20 | 0.39 |
| ▸ | CDK9 | P50750 | 4/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | PLAAT3 | P53816 | 1/20 | 0.36 |
| ▸ | PLAAT5 | Q96KN8 | 1/20 | 0.36 |
| ▸ | PLAAT2 | Q9NWW9 | 1/20 | 0.36 |
| ▸ | PLAAT4 | Q9UL19 | 1/20 | 0.36 |
| ▸ | THRB | P10828 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27094607 | 0.85 | CCNT1 (0.44) | CCNT1CDK9 | |
| SCHEMBL1013879 | 0.83 | CCNT1 (0.39) | MAPTCCNT1CDK9 | |
| SCHEMBL27233661 | 0.83 | CCNT1 (0.39) | ALDH1A1KDM4ECCNT1CDK9KMT2A | |
| SCHEMBL27233590 | 0.81 | KMT2A (0.46) | ALDH1A1MAPTGAAKDM4ECCNT1 | |
| SCHEMBL1011533 | 0.81 | MAPK1 (0.42) | ALDH1A1KDM4ECCNT1CDK9KMT2A | |
| SCHEMBL30903848 | 0.80 | MAPK1 (0.41) | ALDH1A1KDM4ECCNT1CDK9KMT2A | |
| SCHEMBL27233677 | 0.80 | MAPK1 (0.44) | ALDH1A1MAPTGAAKDM4ECCNT1 | |
| SCHEMBL1011032 | 0.80 | MAPK1 (0.41) | ALDH1A1KDM4ECCNT1CDK9KMT2A | |
| SCHEMBL1037249 | 0.80 | FAAH (0.41) | ALDH1A1KDM4ECCNT1CDK9KMT2A | |
| SCHEMBL1013975 | 0.79 | CCNT1 (0.41) | MAPTCCNT1CDK9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260115186-A1 | PIPERIDINE UREA DERIVATIVES FOR CANCER THERAPY | NEUROPN THERAPEUTICS INC. (US) | 2026-04-30 | — | — | US | disclosed |
| US-20260102393-A1 | PIPERIDINE UREA DERIVATIVES FOR TREATMENT OF NEURODEGENERATIVE DISEASES | NEUROPN THERAPEUTICS INC. (US) | 2026-04-16 | — | — | US | disclosed |
| US-20260083718-A1 | PIPERIDINE UREA DERIVATIVES FOR OBESITY THERAPY | ASTRIZI BIO, INC. (US) | 2026-03-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260115186-A1 | PIPERIDINE UREA DERIVATIVES FOR CANCER THERAPY | CHEK1, CHEK2, BUB3 | ALDH1A1 363/4885MAPT 3885/4885GAA 2516/4885 |
| US-20260083718-A1 | PIPERIDINE UREA DERIVATIVES FOR OBESITY THERAPY | GLP1R, GIPR, GPR119 | ALDH1A1 1688/4885MAPT 4672/4885GAA 1485/4885 |
| US-20260102393-A1 | PIPERIDINE UREA DERIVATIVES FOR TREATMENT OF NEURODEGENERATIVE DISEASES | SNCA, PARK7, FAAH | ALDH1A1 201/4885MAPT 1217/4885GAA 272/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.